Background

- Current therapies for chronic hepatitis B (CHB) including HBV DNA < lower limit of quantitation (LLOQ) and ALT or HBsAg <100 IU/mL were noted during the treatment period in 2 of 34 subjects (6%).
- Additional follow up is needed to determine if the addition of IFN to AB treatment is well tolerated and may result in continued HBsAg declines in some subjects.
- There were no SAEs, study discontinuations or AB treatment-related deaths during the study period.
- Sustained virological response (SVR) definition: Sustained HBsAg undetectable, HBV DNA < LLOQ, and HBsAg <100 IU/mL at two consecutive visits at Week 24.
- Subjects with HDV, HIV or HCV infections were randomized at Week 24 into one of 4 groups (stratified by HBsAg level at Week 52): AB 729 + NA + weekly Peg IFN α2a; AB 729 + NA + biweekly Peg IFN α2a; COBRA; and placebo. (N = 9 per group)
- Additional follow up is needed to determine if the addition of IFN to AB treatment is well tolerated and may result in continued HBsAg declines in some subjects.
- There were no SAEs, study discontinuations or AB treatment-related deaths during the study period.
- Sustained virological response (SVR) definition: Sustained HBsAg undetectable, HBV DNA < LLOQ, and HBsAg <100 IU/mL at two consecutive visits at Week 24.
- Subjects with HDV, HIV or HCV infections were randomized at Week 24 into one of 4 groups (stratified by HBsAg level at Week 52): AB 729 + NA + weekly Peg IFN α2a; AB 729 + NA + biweekly Peg IFN α2a; COBRA; and placebo. (N = 9 per group)
- Additional follow up is needed to determine if the addition of IFN to AB treatment is well tolerated and may result in continued HBsAg declines in some subjects.
- There were no SAEs, study discontinuations or AB treatment-related deaths during the study period.
- Sustained virological response (SVR) definition: Sustained HBsAg undetectable, HBV DNA < LLOQ, and HBsAg <100 IU/mL at two consecutive visits at Week 24.
- Subjects with HDV, HIV or HCV infections were randomized at Week 24 into one of 4 groups (stratified by HBsAg level at Week 52): AB 729 + NA + weekly Peg IFN α2a; AB 729 + NA + biweekly Peg IFN α2a; COBRA; and placebo. (N = 9 per group)